In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Some Troubling Numbers For Big Pharma Consolidation

Executive Summary

A recent CenterWatch Inc. study of 11 major pharmaceutical company mergers suggests that the downturn in sales and marketing figures for consolidated firms is accompanied by decreased R&D output.

You may also be interested in...



The Value of Scale in Pharma's Future

Despite the increasingly common perception of the helpless mega-merged giant, vastly increased scale can provide such companies with significant competitive advantages, from which companies were unwilling or unable to benefit in the past. The largest companies, structured properly, should be able to discover disproportionately more compounds; develop them faster; and market them more successfully. But to reap these benefits, the super heavyweight pharmas will, paradoxically, have to learn how to think small.

Electrolyte Supplements’ Benefit For Sodium Level A ‘False Paradigm’ – Study

Stanford University and other researchers concluded that supplements popular with endurance runners can't be relied on to keep essential sodium levels in balance. "Electrolyte supplements are promoted as preventing nausea and cramping caused by low salt levels, but this is a false paradigm. They've never been shown to prevent illness or even improve performance," says lead researcher Grant Lipman.

Biologics Boss: FDA Looking For Alternative Medical Device Sourcing Due To COVID-19

Peter Marks, head of the US FDA’s biologics center, says the agency is looking for alternative sourcing and manufacturing of medical products imported from China, including medical devices, to ward off potential shortages that could result from the ongoing coronavirus crisis and containment.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV001479

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel